Zevra Therapeutics, Inc. (ZVRA) Misses Q1 EPS by $2.25

Zevra Therapeutics, Inc. (NASDAQ: ZVRA) reported Q1 EPS of ($0.06), $2.25 worse than the analyst estimate of $2.19. Revenue for the quarter came in at $25.9 million versus the consensus estimate of $22.49 million.

For earnings history and earnings-related data on Zevra Therapeutics, Inc. (ZVRA) click here.

You May Also Be Interested In

• L3Harris CEO steps down amid conduct review, shares drop
• Bread Financial reports lower loss, delinquency rates in July 2026
• Kuya Silver Reports Q2, 2026 Financial Results - Advances Bethania Mine Development and Drilling Program